GnRH vs LHRH Agonists: Terminology and Clinical Equivalence
GnRH (Gonadotropin-Releasing Hormone) and LHRH (Luteinizing Hormone-Releasing Hormone) are identical hormones with different names—the terms are interchangeable, and "GnRH agonist" and "LHRH agonist" refer to the same class of medications. 1
Nomenclature Clarification
- GnRH and LHRH are the same hormone with two different historical names used in the medical literature 2, 3
- The hormone was initially called LHRH when researchers first identified its role in stimulating luteinizing hormone release 4
- Later research revealed it also stimulates follicle-stimulating hormone (FSH), leading to the more accurate term "Gonadotropin-Releasing Hormone" (GnRH) 4, 5
- Both terms remain in current clinical use, with "GnRH" being more physiologically accurate but "LHRH" still widely used in oncology literature 1
Clinical Medications: Agonists vs Antagonists
The clinically relevant distinction is not between GnRH and LHRH, but rather between agonists and antagonists of this hormone system:
LHRH/GnRH Agonists (Standard Therapy)
- Include leuprolide, goserelin, triptorelin, and buserelin 6, 7
- Bilateral orchiectomy or medical castration with LHRH agonists are the recommended initial treatments for metastatic prostate cancer 1
- These agents are equally effective to surgical castration, available in depot injections (every 1-6 months), and potentially reversible 1
- Critical limitation: cause initial testosterone surge ("flare phenomenon") during the first 1-2 weeks requiring concurrent antiandrogen coverage for 3-4 weeks 1, 8, 9
- Testosterone levels increase above baseline during the first week, then decline to castrate levels by weeks 2-4 1, 9
- This flare can cause tumor progression, ureteral obstruction, spinal cord compression, or bone pain in patients with metastatic disease 1, 10, 9
GnRH/LHRH Antagonists (Alternative Approach)
- Include abarelix and degarelix 4, 7, 11
- Produce immediate testosterone suppression without initial surge or flare phenomenon 4, 7, 12
- Achieve castrate testosterone levels more rapidly than agonists (within days vs 2-4 weeks) 4, 12
- Do not require concurrent antiandrogen administration 7, 11, 12
- Degarelix is currently the only LHRH antagonist approved in the United States for advanced prostate cancer 4
- In castration-naïve patients, LHRH antagonists and agonists are considered clinically similar 3
Practical Clinical Implications
When to Prefer LHRH Agonists:
- Standard first-line therapy for most patients with metastatic prostate cancer 1
- Available in convenient long-acting depot formulations (3-6 month options) 1, 6
- Extensive long-term safety and efficacy data spanning 25+ years 4
- Lower cost compared to antagonists 1
When to Consider LHRH Antagonists:
- Patients requiring rapid testosterone suppression without flare risk 4, 12
- Patients with high metastatic burden at risk for complications from testosterone surge (spinal cord compression, severe bone pain, ureteral obstruction) 1, 12
- Patients who cannot tolerate or have contraindications to antiandrogens needed with agonist initiation 7, 11
- Currently limited by monthly-only formulations and higher cost 11
Common Pitfalls to Avoid:
- Never initiate LHRH agonist therapy without antiandrogen coverage in patients with significant metastatic disease burden 1, 8, 9
- Do not confuse the terminology—GnRH and LHRH refer to the same hormone system 2, 4
- Monitor patients closely during the first 2-4 weeks of LHRH agonist therapy for signs of disease flare 1, 10, 9
- Ensure testosterone levels reach and maintain castrate range (<50 ng/dL) regardless of which agent is used 1, 9